OpenAI Acquires Orchestra Bio

OpenAI says it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. The company states that it is bringing Orchestra's team and technology together with Rosalind, its AI models and tools for life sciences research.

According to OpenAI, developing a new medicine takes roughly 10 to 15 years on average from target discovery to regulatory approval in the United States.

OpenAI states that Orchestra Bio is a platform where people and AI agents work together to advance drug programs. The company added that its partnership with Novo Nordisk aims to translate Novo Nordisk's scale and scientific expertise into faster R&D and commercial execution while maintaining strong governance, while at Moderna, AI is helping teams translate insights from complex data into experimental workflows with the potential to accelerate R&D.